News
Regeneron to buy bankrupt 23andMe, vows ethical use of customer DNA data
Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy auction, and promised to prioritize the ethical use of DNA data from customers using ancestry testing and other services.
23andMe Bankruptcy Saga: Founder Anne Wojcicki Makes Last-Minute Bid for DNA Data
The move marks a turning point in 23andMe’s tumultuous decline. Founded in 2006 by Wojcicki, the company initially gained traction with its saliva-based ancestry kits and went public in 2021. By the end of that year, its valuation peaked at $6 billion.
Me is proposing to reopen its bankruptcy auction to entertain a final offer from a nonprofit operated by its co-founder, ...
The judge overseeing the bankruptcy of 23andMe questioned the limits proposed for a second auction that is designed to push ...
The founder of 23andMe, Anne Wojcicki, has asked a federal bankruptcy court judge to reopen an auction for the genetic ...
A judge overseeing 23andMe’s bankruptcy questioned the implications of a provision in President Donald Trump’s “big beautiful ...
Is this tech company behind CEO's bid for 23andMe genetic data? How Anne Wojcicki's group still could snag 23andMe How Anne ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Human genetics testing firm 23andMe announced Tuesday it will voluntarily delist from the Nasdaq and deregister with the U.S.
Me has a path to a higher purchase price than the $256 million offered by biotech giant Regeneron after the genetic-testing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback